US2020181142A1PendingUtilityA1
Derivatives And Methods Of Treating Hepatitis B Infections
Est. expiryDec 30, 2034(~8.5 yrs left)· nominal 20-yr term from priority
C07D 471/04A61K 45/06C12N 2730/10134A61K 31/437C12N 2730/10111A61K 31/501A61K 39/292A61K 38/212C12N 7/00A61K 31/5377A61P 31/12A61K 31/4375C12N 2730/10171A61K 31/4545
77
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
Claims
exact text as granted — not AI-modified1 . A compound of Formula II
or a pharmaceutically acceptable salt thereof,
wherein
Y is selected from —C(O)— and —SO 2 —;
Z is selected from —(CR 5 R 6 ) m —, —(CR 5 R 6 ) m O—, and —(CR 5 R 6 ) m —NR′—;
R 1 is selected from C 6 -C 12 -aryl and C 1 -C 9 -heteroaryl, wherein aryl and heteroaryl are optionally substituted with 1 or 2 groups each independently selected from —OH, halo, C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, —O—C 1 -C 6 -alkyl, and C 1 -C 6 -alkyl-OH;
R 2 is, at each occurrence, independently selected from H, C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, —O—C 1 -C 6 -alkyl, and C 1 -C 6 -alkyl-OH;
R 3 is H,
R 4 is selected from C 1 -C 6 -alkyl, (CR 8 R 9 ) p —C 3 -C 8 -cycloalkyl, (CR 8 R 9 ) p —C 2 -C 8 -heterocyclyl, (CR 8 R 9 ) p —C 6 -C 12 -aryl, and (CR 8 R 9 ) p —C 1 -C 9 -heteroaryl, wherein alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with 1 or 2 groups, each independently selected from —OH, halo, CN, C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, —O—C 1 -C 6 -alkyl, C(O)N(R f ) 2 , C(O)OR f , —OCH 2 C(O)OR f , —SO 2 R f , and C 1 -C 6 -alkyl-OH;
R 5 is, at each occurrence H,
R 6 is, at each occurrence, H,
R 7 is selected from H, C 1 -C 6 -alkyl, and C 1 -C 6 -alkyl-OH;
R 8 is, at each occurrence, independently selected from H and C 1 -C 6 -alkyl;
R 9 is, at each occurrence, H,
R a H;
R f is, at each occurrence, independently selected from H and C 1 -C 6 -alkyl;
m is 0, 1, or 2;
n is 1; and
p is 0 or 1.
2 - 6 . (canceled)
7 . The compound of claim 1 , wherein
m is 0 or 1; and R 7 is H or C 1 -C 6 -alkyl.
8 . The compound of claim 1 , wherein R 1 is C 6- aryl optionally substituted with halo.
9 . (canceled)
10 . The compound of claim 1 , wherein R 2 is H.
11 . The compound of 1, wherein R 4 is (CR 8 R 9 ) p —C 3 -C 8 -cycloalkyl, (CR 8 R 9 ) p —C 2 -C 8 -heterocyclyl, (CR 8 R 9 ) p —C 6 -C 12 -aryl, or (CR 8 R 9 ) p —C 1 -C 9 -heteroaryl, wherein cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with 1 or 2 groups, each independently selected from —OH, halo, CN, C 1 -C 6 -haloalkyl, —O—C 1 -C 6 -alkyl, C(O)N(R f ) 2 , C(O)OR f , —OCH 2 C(O)OR f , —SO 2 R f , and C 1 -C 6 -alkyl-OH.
12 . The compound of claim 1 , wherein R 4 is (CR 8 R 9 ) p —C 6 -C 12 -aryl or (CR 8 R 9 ) p —C 1 -C 6 -heteroaryl, wherein aryl and heteroaryl are optionally substituted with 1 or 2 groups, each independently selected from —OH, halo, CN, C 1 -C 6 -alkyl, C 1 —O 6 -haloalkyl, C(O)N(R f ) 2 , C(O)OR f , —OCH 2 C(O)OR f , —SO 2 R f , and C 1 -C 6 -alkyl-OH.
13 . The compound of claim 1 , wherein
p is 0 or 1.
14 . (canceled)
15 . The compound of claim 1 , wherein
Y is —C(O)—; Z is NR 7 ; and R 7 is H or C 1-4 -alkyl.
16 - 41 . (canceled)
42 . The compound of claim 1 , wherein the compound is selected from
and pharmaceutically acceptable salts thereof.
43 - 54 . (canceled)
55 . The compound of claim 1 , wherein R 4 is (CR 8 R 9 ) p —C 6 -C 12 -aryl, or (CR 8 R 9 ) p —C 1 -C 9 -heteroaryl, and wherein aryl and heteroaryl are optionally substituted with 1 or 2 groups, each independently selected from —OH, halo, CN, C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, alkyl, and C 1 -C 6 -alkyl-OH.
56 . The compound of claim 1 , wherein the compound of Formula II is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.